Short patent lives jeopardize drug and patient safety

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 4, 2007, Pages 353-357

  Hondeghem, Luc M ^a,d   De Clerck, Fred ^b   Camm, John ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d HPC nv   (Belgium)

Author keywords

Adverse drug reactions; Drug safety; Patent life; Proarrhythmia

Indexed keywords

FEXOFENADINE; SPARFLOXACIN; TERFENADINE;

ADVERSE DRUG REACTION; CLINICAL PRACTICE; DRUG FATALITY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAM; FOLLOW UP; HEALTH CARE COST; HEALTH HAZARD; HEART ARRHYTHMIA; HUMAN; MORBIDITY; NOTE; PATENT; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT PROLONGATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS;

EID: 37349047786     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181514032     Document Type: Note

References (33)

1. DiMasi JA, Hansen RW, Grabowsky HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-185.
2. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood). 2006;25:420-428.
3. United States Patent and Trade Office. Manual of Patent Examining Procedure (MPEP). Edition 8 (E8), August 2001, Last Revision August 2006. Chapter 2700 Patent Terms and Extensions. 2701. Patent Term [R-2]. Available at: www.uspto.gov/main/sitesearch.htm.
4. ICH Harmonized Tripartite Guideline, The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available at: http://www.ich.org/LOB/media/ MEDIA2192.pdf.
5. Usdin S, Haan K. The QT Mandate. BioCentury. 2003;11:A1-A5.
6. Draft Consensus guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14) (2004). Available at: http://www.ich.org.
7. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety marging in drug development. Cardiovasc Res. 2003;58:32-45.
8. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
9. Goodyear M. Learning from the TGN1412 trial. BMJ. 2006;332:677-678.
10. FirstWord. Pfizer halts torcetrapib development over safety concerns. Available at: http://www.firstwordplus.com. Accessed December 4, 2006.
11. Sooriakumaran P. COX-2 inhibitors and the heart: are all coxbs the same? Postgrad Med J. 2006;82:242-245.
12. Bäckström M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004;13:483-487.
13. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385-396.
14. Bakke OM, Manocchia M, de Abajo F, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Br J Clin Pharmacol. 1999;47:307-313.
15. Sha RS. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics. 2006;7:889-908.
16. Lazarou J, Poeranzz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
17. Woosley R. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 1996;36:233-252.
18. Woosley RL. Drug label revisions - guaranteed to fail? JAMA. 2000;284:3047-3049.
19. Curtis LH, Ostbye T, Senderky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135-141.
20. Curtis LH, Ostbye T, Senderky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med. 2004;164:1621-1625.
21. Guédon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relationship to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol. 2004;59:899-904.
22. De Abajo FJ, Rodriguez LAG. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol. 1999;47:307-313.
23. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet. 1997;349:1322.
24. Avorn J. Paying for drug approvals - who's using whom? N Engl J Med. 2007;356:1697-1700.
25. Hennessy S, Strom BL. PDUFA reauthorization - drug safety's golden moment of opportunity? N Engl J Med. 2007;356:1703-1704.
26. McClellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N Engl J Med. 2007;356:1700-1702.
27. Barton JH, Emanuel EJ. The patent-based pharmaceutical development process: rationale, problems, and potential reform. JAMA. 2005;294:2075-2082.
28. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;1:39-43.
29. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
30. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol. 2006;17:337-340.
31. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005;2:758-772.
32. McClellan M. Fundamental improvements in drug safety for the 21st century: time for a systematic, electronic infrastructure. Testimony before the Senate Health, Education, Labor and Pensions Committee, March 14, 2007.
33. MHRA. Press Release: Medicines for Children. Available at: http:// 83.98.30.20/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDoc. Accessed June 1, 2006.